Patents by Inventor Daniel J. Powell

Daniel J. Powell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human alpha-folate receptor chimeric antigen receptor
    Patent number: 9598489
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having alpha-folate receptor (FR-alpha) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR-alpha binding domain is fully human, thereby preventing a host immune response.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: March 21, 2017
    Assignee: The Trustees of the Univeristy of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Compositions and Methods for Treating Cancer
    Publication number: 20170002072
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 5, 2017
    Inventors: Daniel J. Powell, George Coukos
  • Chimeric antigen receptor specific for folate receptor ?
    Patent number: 9446105
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML). The invention also relates to at least one chimeric antigen receptor (CAR) specific to folate receptor beta (FR?), vectors comprising the same, and recombinant T cells comprising the FR? CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a FR? binding domain in combination with a RXR agonist, such as all-trans retinoic acid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 20, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Isolated B7-H4 specific compositions and methods of use thereof
    Patent number: 9422351
    Abstract: The present invention relates to B7-H4-specific chimeric antigen receptor compositions and methods of use thereof.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: August 23, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160222119
    Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.
    Type: Application
    Filed: January 28, 2016
    Publication date: August 4, 2016
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Nathalie SCHOLLER, Denarda DANGAJ, Aizhi ZHAO, Daniel J. POWELL
  • Compositions and methods for treating cancer
    Patent number: 9402865
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: August 2, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, George Coukos
  • CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION
    Publication number: 20160215262
    Abstract: The invention includes compositions and methods to rapidly isolate and culture cells that are potent for use in adoptive immunotherapy. In one embodiment, the isolated cells of the invention are tumor infiltrating lymphocytes (TIL) that express CD137 (also known as 4-1BB and TNFSFR9).
    Type: Application
    Filed: September 16, 2014
    Publication date: July 28, 2016
    Inventor: Daniel J. Powell, JR.
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR -EXPRESSING CELLS
    Publication number: 20160185861
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: December 28, 2015
    Publication date: June 30, 2016
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Zoe Zheng
  • Isolated B7-H4 specific compositions and methods of use thereof
    Patent number: 9279008
    Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: March 8, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
    Patent number: 9272002
    Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with dysregulated expression of mesothelin. In one embodiment, the invention relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target mesothelin.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 1, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Daniel J. Powell, Jr., Nathalie Scholler
  • HUMAN ALPHA-FOLATE RECEPTOR CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20150225480
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having alpha-folate receptor (FR-alpha) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR-alpha binding domain is fully human, thereby preventing a host immune response.
    Type: Application
    Filed: October 3, 2013
    Publication date: August 13, 2015
    Inventor: Daniel J. Powell, JR.
  • ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20140308259
    Abstract: The present invention relates to B7-H4-specific chimeric antigen receptor compositions and methods of use thereof.
    Type: Application
    Filed: November 5, 2012
    Publication date: October 16, 2014
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • FULLY HUMAN, ANTI-MESOTHELIN SPECIFIC CHIMERIC IMMUNE RECEPTOR FOR REDIRECTED MESOTHELIN-EXPRESSING CELL TARGETING
    Publication number: 20140301993
    Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with dysregulated expression of mesothelin. In one embodiment, the invention relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target mesothelin.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 9, 2014
    Inventors: Daniel J. Powell, JR., Nathalie Scholler
  • ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20140294861
    Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.
    Type: Application
    Filed: February 17, 2014
    Publication date: October 2, 2014
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR FOLATE RECEPTOR BETA
    Publication number: 20140286973
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML). The invention also relates to at least one chimeric antigen receptor (CAR) specific to folate receptor beta (FR?), vectors comprising the same, and recombinant T cells comprising the FR? CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a FR? binding domain in combination with a RXR agonist, such as all-trans retinoic acid.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: The Trustees of The University of Pennsylvania
    Inventor: Daniel J. Powell, JR.
  • Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens
    Publication number: 20140234348
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 21, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, JR.
  • Use of a Trans-Signaling Approach in Chimeric Antigen Receptors
    Publication number: 20140099309
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 10, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, JR., Carl H. June
  • Compositions and Methods for Treating Cancer
    Publication number: 20140050708
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Application
    Filed: January 18, 2012
    Publication date: February 20, 2014
    Inventors: Daniel J. Powell, George Coukos